<DOC>
	<DOCNO>NCT01584284</DOCNO>
	<brief_summary>The purpose study determine safety tolerability GL-ONC1 administer intravenously combination radiation therapy cisplatin ( CDDP ) patient locoregionally advanced head neck cancer .</brief_summary>
	<brief_title>Safety Study Attenuated Vaccinia Virus ( GL-ONC1 ) With Combination Therapy Head &amp; Neck Cancer</brief_title>
	<detailed_description>GL-ONC1 , oncolytic vaccinia virus , show ability preferentially locate , colonize destroy tumor cell 40 different human tumor . A First-in-Man , Phase I clinical study focus safety tolerability GL-ONC1 intravenously administer patient variety advance solid tumor entity show GL-ONC1 well-tolerated therapeutic dose level , document evidence antitumor activity . Preclinical study show synergistic effect use chemotherapy ( Cisplatin ) viral therapy GL-ONC , well favorable result cancer cell irradiate treat GL-ONC1 animal model . This Phase I study seeks evaluate safety , tolerability early sign efficacy GL-ONC1 administer intravenously combination standard care ( SOC ) radiation therapy ( RT ) cisplatin ( CDDP ) patient locoregionally advanced head neck cancer . Patients individually assess safety dose limit toxicity . Viral colonization tumor , replication anti-tumoral activity also evaluate .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Confirmed diagnosis histologically cytologically document Stage III IVB primary , nonmetastatic head neck cancer newly diagnose patient prior diseaserelated treatment ( e.g. , chemotherapy , radiation treatment , surgery , etc. ) . American Joint Committee Cancer ( AJCC ) Stage IIIIVB disease ( 2010 manual , 7th edition ) , base standard diagnostic workup . 18 year old . ECOG performance status ≤ 2 . Laboratory data obtain within 14 day prior Treatment Day 1 , adequate hepatic renal function define follow : Absolute neutrophil count ( ANC ) ≥ 1,800 cells/mm3 ; Platelets ≥ 100,000 cells/mm3 ; Hemoglobin ≥ 8.0 g/dL ; Bilirubin ≤ 1.5 mg/dL ; AST ALT ≤ 2× upper limit normal ( ULN ) ; Serum creatinine ≤ 1.5 mg/dL ; Creatinine clearance ( CC ) ≥ 50 mL/min . Pulse oximetry read 92 % high rest room air . Signed informed consent Women childbearing potential must negative serum pregnancy test agree practice effective birth control treatment phase 60 day last virus application . Male patient must agree practice effective birth control study 60 day follow administration last treatment virus . Clinical , radiographic , pathologic evidence distant metastatic disease . Patients fever , active immunosuppressive systemic infection suppress immune system , include AIDS HIV positivity know hepatitis infection ( HCV HBC . Eligible patient must HIV test conduct within 4 week prior study enrollment negative test result . Any form prior anticancer treatment . Diseaserelated surgery , exclude biopsy . Patients CNS ( Central Nervous System ) tumor . Any open wound . Concurrent small pox vaccination 4 week study therapy study treatment . Patients immunosuppressive therapy immune system disorder , include autoimmune disease . Prior splenectomy . Previous organ transplantation . Patients clinically significant dermatological disorder , judge clinical investigator ( e.g. , eczema psoriasis ) , skin lesion ulcer , history atopic dermatitis , history Darier 's disease ( Keratosis Follicularis ) . Clinically significant cardiac disease ( New York Heart Association : Class III IV ) . Dementia alter mental status would prohibit informed consent . Known allergy ovalbumin egg product . Prior gene therapy treatment prior therapy cytolytic virus type .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Genelux</keyword>
	<keyword>Genelux Corporation</keyword>
	<keyword>GL-ONC1</keyword>
	<keyword>Vaccinia</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Oncolytic Virotherapy</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
</DOC>